An attempt was made to establish an SCID-hu murine model of long-term human hematopoiesis by coimplantation of a bone fragment and bone marrow (BM) cells from an adult human. The SCID-hu mice were treated with a cytokine mixture (recombinant human stem cell factor, interleukin-3, granulocytelmacrophage colony-stimulating factor, and granulocyte colony-stimulating factor) for 4 months and were then maintained for further 8 months under cytokinefree conditions. In the peripheral blood, spleen, and im-ECENTLY, THE HUMAN hematopoietic system in mice with severe combined immunodeficiency (SCID) has been studied as a model of human diseases such as acquired immunodeficiency syndrome,'.2 leukemidlymphorna,'"'' several autoimmune diseases,""4 or allergies." These models were established by implantation of patients' peripheral blood (PB) cells, bone marrow (BM) cells, lymph node cells, or thymic cells in the kidney capsule, peritoneal cavity, subcutaneous region, or PB of SCID mice. The models have provided much important information on the mechanisms of various diseases and for the development of therapeutic method^.^^^^^'^ Several studies aimed at establishing an animal model of normal human hematopoiesis by transferring human hematopoietic progenitor cells into SCID mice have been performed.27"" However, these have met with only limited success. In the majority of studies, human blood cells were detectable for only a few months. One of the reasons for this is that the microenvironments for hematopoiesis in which human cells can proliferate and differentiate are only those of murine origin (eg, the murine BM or spleen).
ECENTLY, THE HUMAN hematopoietic system in mice with severe combined immunodeficiency (SCID) has been studied as a model of human diseases such as acquired immunodeficiency syndrome,'.2 leukemidlymphorna,'"'' several autoimmune diseases,""4 or allergies." These models were established by implantation of patients' peripheral blood (PB) cells, bone marrow (BM) cells, lymph node cells, or thymic cells in the kidney capsule, peritoneal cavity, subcutaneous region, or PB of SCID mice. The models have provided much important information on the mechanisms of various diseases and for the development of therapeutic method^.^^^^^'^ Several studies aimed at establishing an animal model of normal human hematopoiesis by transferring human hematopoietic progenitor cells into SCID mice have been performed.27"" However, these have met with only limited success. In the majority of studies, human blood cells were detectable for only a few months. One of the reasons for this is that the microenvironments for hematopoiesis in which human cells can proliferate and differentiate are only those of murine origin (eg, the murine BM or spleen).
Because of the complexity of the mechanisms related to hematopoiesis, maintenance of human stem cells in a microenvironment of human origin seems preferable. This could be achieved by implanting both a human bone fragment and BM cells into a SCID mouse, which means that stromal cells and hematopoietic stem cells would be compatible as a functional unit. Since 1990, Namikawa et al," Peault and colleague^,'^^'^ and Vormoor et al '4 have reported that transplantation of fetal thymus, fetal liver, or cord blood cells planted bone fragments in the SCID-hu mice that had received both a bone fragment and BM cells, human CD59' cells were detected 1 year after transplantation; however, they were not detectable in SCID-hu mice that had received either a bone fragment or BM cells only. Thus, implantation of both a bone fragment and BM cells appears to provide a model of long-term adult human hematopoiesis in SCID mice.
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can reconstitute the human hematopoietic system in SCIDhu mice. In 1992, Kyoizumi and colleagues showed that implantation of human fetal bone fragments provided longterm maintenance of human hematopoiesis in SCID m i~e . '~.~' However, it has proved difficult to reconstitute hematopoiesis originating from human adult BM cells, because embryonic and adult hematopoietic progenitors differ with respect to their cycling response profiles to hematopoietic factor^,'"^' and differentiation capacitie~.~*,~' Accordingly, no previous studies have succeeded in reconstruction of adult human hematopoiesis in a SCID-hu model. In this study, we showed that implantation of a human bone fragment and BM cells in SCID mice could reconstruct and maintain human hematopoiesis for 1 year after transplantation.
MATERIALS AND METHODS
Reagents. Recombinant human stem cell factor (rhSCF), rh interleukin-3 (rhIL-3), rh granulocyte-macrophage colony-stimulating factor (rhGM-CSF), and rh granulocyte CSF (rhG-CSF) were kindly supplied by Kirin Brewery CO Ltd (Tokyo, Japan). Trimetoprim and sulfamethoxasole were purchased from Sigma Chemical CO (St Louis, MO).
Animals. Female C B -17/lcrCrl-scid Jcl mice (5 weeks old) were purchased from Nihon Clea (Tokyo, Japan) and maintained at the National Cancer Center Research Institute (Tokyo, Japan) under standard conditions, according to the Institutional Guidelines. The mice were treated with TMS suspension (1.25 mg of trimethoprim and 6.25 mg of sulfamethoxasole) via their drinking water 2 weeks after transplantation. The mice were anesthetized during all operative procedures with 65 mglkg sodium pentobarbital administered by intraperitoneal injection.
Human bones and BM cells. Adult human ribs were obtained with informed consent from lung cancer patients (60-to 73-yearold men) who underwent lung lobectomy between January and July 1993 at the Division of Thoracic Surgery, National Cancer Center Central Hospital. The ribs were preserved immediately in ice under sterile conditions. They were cut into bone fragments (1 cm X 2 cm ) with all edges opened and were then implanted into the subcutaneous region of SCID mice within 30 minutes.
Human BM cells were collected from the residual bone fragments of the same donors. The cells were stored in mouse semm with 10% dimethyl sulfoxide in liquid nitrogen until use. We checked by light microscopy that the BM cells responded to optimal cytokine stimulation (GM-CSF and G-CSF) to form granulocyte colonies and granulocyte-macrophage colonies. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From CA) delivering a cytokine mixture of rhSCF ( I pglmouseld), rhlL-3 ( I pglmouseld), rhGM-CSF ( I pglmouseld), and rhG-CSF ( I pgl mouseld) in saline plus 19 SClD serum was implanted beside the bone fragment at the same time. Twenty days after bone implantation. BM cells ( I to S X 10' cellslmouse) from the same donor were infused into the SCID mouse through the tail vein. Further treatment with the cytokine mixture was performed by subcutaneous injection every 3 days for 4 weeks and then every 2 days for a further 12 weeks. followed by 8 months of maintenance under cytokine-free conditions. We designated the SCID-hu mice cotransplanted with a human bone fragment and BM cells "BTlBMT-SCID."
As controls. SCID mice transplanted with only a bone fragment (BT-SCID) and SClD mice transplanted with only BM cells (BMT-SCID), which were administered the same cytokine trcatmcnts, were prepared. Detection ?f the lntnlcrn CD59 ~C'IIC' in s p l w n cc4l.s. Detection of the CD59 gene in the spleen cells of SCID-hu mice I year after transplantation was performed by the polymerase chain reaction (PCR) protocol. Genomic DNA of SCID-hu spleen cells was collected by the standard protocol described Oligonuclcotide primers were synthesized by the phosphoramidite method using an automated DNA synthesizer (Model 391 PCR-mute EP: Applied Biosystems, Foster City. CA) and purified on oligonucleotide purification cartridge (OPC) columns (Applied Biosystems). For aniplification of human CD59 DNA. a CD-S9/1 sense primer, S'-TGG-GTAAAGTAGGGTTGGAG-3'. and a CDS9/2 antisense primcr. For Histologic examination of transplanted hone fragments. Conventional histologic sections (5-pm thick) were cut from formalin-fixed, paraffin-embedded materials. The sections were mounted on poly-L-lysine-coated glass slides and were air-dried overnight at room temperature. Histologic examination was performed by standard light microscopic evaluation of sections stained with hematoxylin and eosin.
Detection of human CD59 gene in hone xenografts. DNA of the cells in bone xenografts 1 year after bone implantation was eluted from paraffin-embedded samples (see Fig 4C) as described prev i o u~l y ?~.~~ For amplification of human CD59 DNA, a CD-59/1 sense primer S'-GCTITCCTTC7TCTCACCTG-3', and a CD5912 antisense primer, S'-AATGGGGACACTI%CITGCT-3', were used. The predicted amplification product was the 121 bp of human CD59, exon 2 DNA sequence. The samples were overlaid with 100 pL of mineral oil, denatured for 1 minute at 95°C. and subjected to 40 cycles of PCR (at 95°C for I minute, at 55°C for 1 minute, and at 72°C for 2 minutes) in a Thermal Cycler. A last single cycle of 95°C for 1 minute, 55°C for I minute, and 72°C for 7 minutes was performed. The amplification products were analyzed by gel electrophoresis on 10% polyacrylamide gel (Daiichi-kagaku, Tokyo, Japan) and stained with ethidium bromide.
RESULTS

Table 1. Percentages of CD59' Cells in SCID-hu Mice
The intensities of forward scatter and side scatter qf PR cells from SCID-hu mice. Figure I showed the intensities of forward scatter versus side scatter of the PB cells from indicated by the ellipse in gate 1 (Fig l A) Table I shows the percentages of CDS9' cells calculated using the formula described in Materials and Methods. The proportion of CDS9' cells in BT-SCID was 13.7% at 4 months and 20 days after bone transplantation, but none could be found at 8 months after transplantation. In BMT-SCID, although CD59' cells constituted 5.0% of the population 8 months after BM transplantation, none were found at 12 months after transplantation. In BT/BMT SCID, CD59' cells were present at 15.2%. 1 1 .8%, and 6. I % 4, 8, and 12 months after bone transplantation, respectively. The percentage of the particular cell population indicated in gate 1 parallelled the percentage of CD59' cells (Fig 1 and Table l ) . PCR examination showed that human CD59 exon 2 DNA was positive in the spleen cells of BT/ BMT SCID 12 months after transplantation but was negative in those of BT-SCID and BMT-SCID (Fig 3) .
Histologic findings o f transplanted hone ,fragments nnd
detection of human CDS9 gene. Figure 4 shows histologic sections of bone grafts in BT/BMT SCID. Hematopoietic cells were found in the BM of the grafts 4 months after bone transplantation (Fig 4A) . However. at I year after bone transplantation, necrotic and/or fibrous changes were found in the BM of the xenograft, where no clear foci of hematopoietic cells were evident (Fig 4B) . Hematopoietic foci were observed only in the area facing the osmotic pump (Fig 4C) . PCR examination also confirmed the presence of hu.man CD59 gene-positive cells in this area of the bone xenograft (Fig S) .
DISCUSSION
In this study. we aimed at establishing SCID-hu murine model of long-term human hematopoiesis by coimplantation of a bone fragment and BM cells from an adult human. Figures I and 2 showed the existence of the typical cell population resembling that of human cells in PB from BT/ BMT SClD I year after BMT. In previous studies. human hematopoetic cells in animal models were distinguished from those of the recipient animals by immunocytochemical analysis using MoAbs against surface markers or by fluorescence used a FITC-conjugated anti-CDS9 MoAb to distinguish human-derived cells form mouse-derived cells. CD59 antigen was expressed on many hematopoietic and nonhematopoietic cells from humans. The particular cell population indicated in gate 1 in Fig1 A was clearly bright positive for CD59 expression (Fig 2) . Human CD59' cells in BT/BMT SCID 1 year after bone transplantation were present at 6.1%. PCR examination showed that human CD59 exon 2 DNA was positive in the spleen cells of BT/BMT SCID 1 year after transplantation (Fig 3) . These data suggested that normal human hematopoietic cells were present in the PB and in the spleens from BT/BMT-SCID. Some previous reports have indicated that cytomegalovirus-transformed human cells can survive in SCID-hu mice for a long time.?.' The spleen cells of all SCID-hu mice used in our experiment were negative for cytomegalovirus infection in PCR examinations (data not shown).
It was expected that mature human-derived blood cells might indicate a xenograft reaction in SCID mice. A graftversus-host reaction in SCID-hu mice has been observed by some40.51 but not all"" groups. In our models, no evidence of graft-versus-host reaction was observed.
The BT-SCID and BT/BMT-SCID showed loss of hair around the bone xenograft, whereas the hair of BMT-SCID was not affected. The loss of hair in BT-SCID mice recovered after termination of the cytokine treatment, but that in BT/BMT-SCID continued for over 1 year. The bone xenograft in BT-SCID was forced out from the skin. but that of BT/BMT-SCID was not. The reason for this phenomenon is now being investigated.
Angiogenesis into the implanted bone fragment was found in BTIBMT-SCID but not in BT-SCID. The angiogenesis was observed in the area that faced the cytokine-delivering osmotic pump. We examined this area in the samples histologically after staining them with hematoxylin-eosin. Hemain situ hyhridization.~.7.?7.?Y.").'?-"'. 47 . JX In our experiment, we
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From topoietic cells were found in the area facing the osmotic pump 1 year after bone transplantation (Fig 4C) . The cells in this field responded to optical rhGM-CSF stimulation to form GM-CSF colonies (3 colonies were detected; data not shown). Because rhGM-CSF showed no cross-reactivity with mouse GM-CSF, the GM colony formation response to human GM-CSF indicated that human hematopoietic cells were present in the bone xenograft. PCR examination also confirmed the presence of human CD59 gene-positive cells in this area of the bone xenograft (Fig 5) . Because mousederived cells were human CD59-, these results indicated the existence of human cells in the implanted bone fragment.
These findings indicated that transplantation of both a human bone fragment and BM cells with long-term cytokine treatment could provide a stromal microenvironment suitable for human hematopoietic progenitor cells and maintain it for a long time. In our study, because we did not have a sufficiently large sample for determining the maturation of human cells in the bone xenograft, it was not clear whether pluripotent stem cells were present in the implanted bone fragment. The differentiation of human-derived PB cell into lymphoid, erythroid, myelomonocytic, and megakaryocytic cells was not clear, because antibodies against human CD4, CD8, and CD3 were cross-reactive with mouse spleen cells in our study.
SCID-hu mice have already been used as models of leukemia, lymphoma, acquired immunodeficiency syndrome, and some autoimmune disease^."'^ Our aim is to study the further application of SCID-hu models for in vivo evaluation of immunotherapy, especially immunogene therapy. Some reports have suggested the usefulness of huPBL-SCID mice as the models of i m m~n o t h e r a p y ?~*~~*~~~~~~~~ However, because the percentage of human cells in SCID-hu mice was very low, we could not use this model as a tool for investigating immunotherapy. Total body or treatment with antiasialo GM1 a n t i b~d y~~*~~c o u l d augment the transplantability of human cells in SCID-hu mice. Therefore, we are planning to transplant a human bone fragment and BM cells into SCID mice treated with antiasialo GM1 antibody to increase the transplantability of human cells.
Another problem is that other human lymphoid organs such as lymph nodes can not be implanted in our SCID-hu model mice. For a normal immune response against cancer, implantation of these organs might be necessary.
We have already confirmed that a high degree of transplantability of lung cancer cells into SCID mice can be obtained. At the present stage, although there are still some problems to be solved, long-term adult human hematopoiesis in SCID-hu mice achieved by cotransplantation of both a bone fragment and BM cells in conjugation with long-term cytokine treatment is thought to be an important first step for producing a useful model of immunotherapy. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
